Core Insights - GL Capital Management GP Limited reduced its stake in Lee's Pharmaceutical Holdings Limited (00950) by 2.942 million shares at a price of HKD 1.8776 per share, totaling approximately HKD 5.5239 million [1] - After the reduction, GL Capital Management holds approximately 39.0995 million shares, representing a 6.64% ownership stake in the company [1] Related Parties - The transaction involves other related parties including Assicurazioni Generali SpA, Li Zhenfu, and Lion River I N.V. [1]

Group 1 - GL Capital Management GP Limited reduced its stake in Lee's Pharmaceutical Holdings Limited (00950) by 2.942 million shares at a price of HKD 1.8776 per share, totaling approximately HKD 5.5239 million [1] - After the reduction, GL Capital Management's remaining shareholding is approximately 39.0995 million shares, representing a holding percentage of 6.64% [1] - The transaction involves other related parties, including Assicurazioni Generali SpA, Li Zhenfu, and Lion River I N.V. [1]

致：香港交易及結算所有限公司 公司名稱: 李氏大藥廠控股有限公司 本月底法定/註冊股本總額： HKD 50,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | 李氏大藥廠控股有限公司 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 HKD | | | 0.05 HKD | | | 50,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 1,000,000,000 HKD | ...

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Lee's Pharmaceutical Holdings Limited, which rose over 21% and is currently trading at 21 HKD, with a trading volume of 31.96 million HKD [1] - The company reported a mid-term revenue of 695 million HKD, reflecting a year-on-year increase of 5.5%, driven by strong sales performance of its product portfolio [1] - The net profit attributable to shareholders for the first half of 2025 was 67.185 million HKD, representing a year-on-year increase of 7.5%, indicating a sustainable growth trajectory and improved operational strength [1] Group 2 - The company announced that its subsidiary, Zhaoke Pharmaceutical, received approval for a new indication for its anti-PD-L1 monoclonal antibody, Socazolimab, for use in combination chemotherapy as a first-line treatment for extensive-stage small cell lung cancer [1] - This approval marks the second indication for Socazolimab, following its initial conditional approval for the treatment of recurrent or metastatic cervical cancer [1]

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) experienced a significant stock price increase, rising over 21% at the close, with a current increase of 16.02% to HKD 21, supported by strong mid-term performance and new product approvals [1] Financial Performance - The company reported a revenue of HKD 695 million, reflecting a year-on-year increase of 5.5%, driven by robust sales performance across its product portfolio [1] - For the first half of 2025, the profit attributable to shareholders was HKD 67.185 million, marking a 7.5% increase compared to the previous year [1] - Earnings per share stood at HKD 0.1141 [1] Product Development - Lee's Pharmaceutical announced that its subsidiary, Zhaoke Pharmaceutical, received approval for a new indication for the anti-PD-L1 monoclonal antibody, Socazolimab, for use in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer [1] - This approval represents the second indication for Socazolimab, following its initial conditional approval for the treatment of recurrent or metastatic cervical cancer [1]

Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * （於開曼群島註冊成立之有限公司） （股份代號：950） 提名委員會之職權範圍 2. 組 成 * 僅供識別 – 1 – 4.1 提 名 委 員 會 主 席 或（如 其 未 克 出 席）提 名 委 員 會 其 他 成 員（須 為 獨 立 非 執 行 董 事）須 出 席 本 公 司 之 股 東 週 年 大 會，就 股 東 對 提 名 委 員 會 事 務 及 責 任 之 提 問 作 出 回 應。 – 2 – 3.1 提 名 委 員 會 須 每 年 至 少 會 面 一 次。提 名 委 員 會 成 員 可 隨 時 於 認 為 必 要 之 情 況 下 召 開 會 議。 3.2 除 非 獲 提 名 委 員 會 全 體 成 員 豁 免，否 則 須 為 所 有 會 議 發 出 正 式 通 告。 不 論 通 告 期 之 長 短，提 名 委 員 會 成 員 出 席 會 議 將 被 視 作 豁 免 所 需 通 告 規 定 處 理。 3.3 提 名 委 員 會 議 事 所 需 之 法 定 人 數 須 為 兩 名 提 名 委 員 會 成 ...

Group 1 - The company reported a revenue of HKD 695 million for the first half of 2025, representing a year-on-year increase of 5.5% [1] - The net profit for the same period was HKD 67.185 million, showing a year-on-year growth of 7.5% [1] - The company proposed an interim dividend of HKD 0.022 per share [1]

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) reported a revenue of HKD 695 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.5% [1] - The profit attributable to the company's owners was HKD 67.185 million, reflecting a year-on-year increase of 7.5% [1] - Earnings per share were HKD 0.1141, with an interim dividend proposed at HKD 0.022 per share [1] Revenue Growth Drivers - The revenue increase was primarily driven by strong sales performance across the company's product portfolio [1] - Notable growth was observed in rare disease and specialty products, with "Qufrile" injection achieving a robust growth of 31.4% and "Buleidining" rising by 12.9% [1] - In the traditional product mix of introduced products, "Fipril" saw a significant growth of 33.3%, regaining its position as the largest contributor after last year's transitional phase [1] Impact of Procurement Programs - The centralized procurement program played a crucial role in driving revenue growth, with "Sodium Dexamethasone Injection" and "Nacogdocevir Calcium Injection" recording growth rates of 18.8% and 11.3%, respectively [1] - The improved performance of these products supported overall revenue growth and helped offset the impact of sales slowdowns in several other products during the review period [1]

Group 1 - The core viewpoint of the article highlights the steady growth of Lee's Pharmaceutical Holdings Limited, with a revenue of HKD 695 million for the first half of 2025, representing a 5.5% increase compared to the same period last year [1] - The company's profit attributable to shareholders for the first half of 2025 was HKD 67.185 million, reflecting a year-on-year increase of 7.5%, indicating a sustainable growth trajectory and strengthened operational capabilities [1] - Earnings per share for the company stood at HKD 0.1141 [1] Group 2 - The company holds a 65% stake in its subsidiary, China Oncology Medical Limited (COF), which focuses on research and development in oncology, particularly in the field of immuno-oncology therapies [1] - COF has established a robust pipeline of oncology assets, including six innovative assets and four generic drugs, developed through a combination of internal research and licensing agreements [1] - In July 2025, the injection of Socazoli was approved by the National Medical Products Administration for a new indication, marking its second approved indication after initial conditional approval for the treatment of recurrent or metastatic cervical cancer [1]

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) reported a revenue of HKD 695 million for the six months ending June 30, 2025, representing a year-on-year increase of 5.5% [1] - The profit attributable to the company's owners was HKD 67.185 million, up 7.5% year-on-year, with earnings per share at HKD 0.1141 and an interim dividend of HKD 0.022 per share proposed [1] Revenue Growth - The revenue increase was primarily driven by strong sales performance across the company's product portfolio [1] - Notable growth was observed in rare disease and specialty products, with a 31.4% increase in sales of the injection product Qufrener (芮旎尔®) and a 12.9% increase in Budesonide (布累迪宁®) [1] - The introduced product Fipril (菲普利®) saw a significant growth of 33.3%, regaining its position as the largest contributor after a transitional phase last year [1] Impact of Procurement Programs - The centralized procurement program played a crucial role in revenue growth, with the injection product Sodium Dexamethasone (立畅青®) and Enoxaparin Sodium (立腾菁®) achieving growth rates of 18.8% and 11.3%, respectively [1] - The improved performance of these products supported overall revenue growth and helped offset the impact of sales slowdowns in several other products during the review period [1]